AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Zacks News
AngioDynamics (ANGO) Up 10.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat
by Zacks Equity Research
AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.
AngioDynamics (ANGO) Down 11.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering
by Zacks Equity Research
AngioDynamics, Inc. (ANGO) announced that it has priced its underwritten public offering of 2.35 million shares of common stock.
5 Cheap Value Stocks to Tame a Capricious Market in Q2
by Zacks Equity Research
Given the volatile backdrop in the U.S. investment markets, we take a look at five companies which are great value bargains and poised for stellar gains in the second quarter that has just begun.
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.
AngioDynamics Microwave Tissue Ablation System Now CE Marked
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, recently announced the receipt of CE mark for Solero Microwave Tissue Ablation (MTA) System.
AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO) reported adjusted earnings of 19 cents per share in the second quarter of fiscal 2017 beating the Zacks Consensus Estimate by 3 cents.
Zacks.com featured highlights: First American Financial, AngioDynamics, Microsemi, Thermo Fisher Scientific and F5 Networks
by Zacks Equity Research
Zacks.com featured highlights: First American Financial, AngioDynamics, Microsemi, Thermo Fisher Scientific and F5 Networks
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
New Strong Buy Stocks for November 3rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
New Strong Buy Stocks for November 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
New Strong Buy Stocks for October 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
What's Your Stock's Price Target?
by Kevin Matras
Kevin Matras explains how to calculate a stock's price target and how to find stocks currently trading below them. Highlighted stocks include MTOR, LEN, RFMD, FFIV and ANGO.